デフォルト表紙
市場調査レポート
商品コード
1481014

ジェネリック注射剤の世界市場

Generic Injectables

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
ジェネリック注射剤の世界市場
出版日: 2024年05月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ジェネリック注射剤の世界市場、2030年には2,275億米ドルに達する見込み

2023年に1,126億米ドルと推定されたジェネリック注射剤の世界市場は、2023年から2030年にかけてCAGR 10.6%で成長し、2030年には2,275億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである大型分子注射剤は、CAGR 11.4%を記録し、分析期間終了時には1,569億米ドルに達すると予想されます。低分子注射剤セグメントは、今後7年間のCAGRが8.8%と予測されています。

米国市場は300億米ドル、中国はCAGR14.3%で成長すると予測

米国のジェネリック注射剤市場は、2023年には300億米ドルに達すると推定されます。世界第2位の経済大国である中国は、2030年までに515億米ドルの市場規模に達すると予測され、分析期間2023年から2030年のCAGRは14.3%です。その他の注目すべき地域市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて7.7%と8.4%の成長が予測されています。欧州では、ドイツがCAGR約8.2%で成長すると予測されています。

2024年の魅力的な新レポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析(好調/活発/ニッチ/マイナー)

専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的な先見性をもって投資判断に臨むことが、生き残りのために重要であることに変わりはないです。

調査対象企業の例(全41件)

  • Baxter International, Inc.
  • Biocon Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16423

Global Generic Injectables Market to Reach $227.5 Billion by 2030

The global market for Generic Injectables estimated at US$112.6 Billion in the year 2023, is expected to reach US$227.5 Billion by 2030, growing at a CAGR of 10.6% over the period 2023-2030. Large Molecule Injectables, one of the segments analyzed in the report, is expected to record 11.4% CAGR and reach US$156.9 Billion by the end of the analysis period. Growth in the Small Molecule Injectables segment is estimated at 8.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $30 Billion, While China is Forecast to Grow at 14.3% CAGR

The Generic Injectables market in the U.S. is estimated at US$30 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$51.5 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 41 Featured) -

  • Baxter International, Inc.
  • Biocon Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Generic Injectables - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Generic Injectables Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Generic Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Generic Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Generic Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Large Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Large Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Small Molecule by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Small Molecule by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Vials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Vials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Vials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Premix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Premix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Premix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Prefilled Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Prefilled Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Prefilled Syringes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Ampoules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Ampoules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Ampoules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Container Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Container Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Container Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: World 16-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Canada 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Japan 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Japan 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 92: China Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: China 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: China 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: China 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: China 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Generic Injectables by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Generic Injectables by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Generic Injectables by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 119: France Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: France 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: France 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: France 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: France 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Germany 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Germany 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Italy 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Italy 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 155: UK Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: UK 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: UK 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: UK 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: UK 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Spain 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Spain 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Russia 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Russia 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Europe 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Europe 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Generic Injectables by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for Generic Injectables by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Australia 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Australia 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 230: India Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: India 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: India 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: India 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: India 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: South Korea 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: South Korea 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Generic Injectables by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Generic Injectables by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for Generic Injectables by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Argentina 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Argentina 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Brazil 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Brazil 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Mexico 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Mexico 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Rest of Latin America 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Rest of Latin America 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Generic Injectables by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Generic Injectables by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for Generic Injectables by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 352: Iran 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 355: Iran 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 364: Israel 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 367: Israel 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 376: Saudi Arabia 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 379: Saudi Arabia 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 388: UAE 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 391: UAE 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 400: Rest of Middle East 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 403: Rest of Middle East 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Generic Injectables Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Generic Injectables by Application - Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for Generic Injectables by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Infectious Diseases, Diabetes, Immunology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Generic Injectables by Product - Large Molecule and Small Molecule - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Generic Injectables by Product - Large Molecule and Small Molecule Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for Generic Injectables by Product - Percentage Breakdown of Value Sales for Large Molecule and Small Molecule for the Years 2014, 2024 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Generic Injectables by Container Type - Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 412: Africa 16-Year Perspective for Generic Injectables by Container Type - Percentage Breakdown of Value Sales for Vials, Premix, Prefilled Syringes, Ampoules and Other Container Types for the Years 2014, 2024 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Generic Injectables by Route Of Administration - Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 415: Africa 16-Year Perspective for Generic Injectables by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Subcutaneous and Other Routes of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION